ArticleF1000Research
Adaptive platform trials using multi-arm, multi-stage protocols: getting fast answers in pandemic settings.
Article in F1000Research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Characteristics, Progression, and Output of Randomized Platform Trials: A Systematic Review.JAMA network open · 2024Pooled it
- Reflections on Participation in a Trial on Hydroxychloroquine as Prevention for COVID-19 among Health Workers in Niger.The American journal of tropical medicine and hygiene · 2023Trial
- Inhaled ciclesonide for outpatient treatment of COVID-19 in adults at risk of adverse outcomes: a randomised controlled trial (COVERAGE).Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2022Trial
- Trial
- Regulating nanomedicines: challenges, opportunities, and the path forward.Nanomedicine (London, England) · 2025Review
- A brief review on the lessons learned from COVID-19 on drug discovery and research.Medicine and pharmacy reports · 2024Review
- Mapping decision-making pathways: Determination of intervention entry points for diagnostic tests in suspected serious infection.NIHR open research · 2024Article
- Co-designing and pilot testing an infographic to support patients/families through the REMAP-CAP consent process: a mixed-methods study protocol.Pilot and feasibility studies · 2023Article
- A multi-disciplinary commentary on preclinical research to investigate vascular contributions to dementia.Cerebral circulation - cognition and behavior · 2023Review
- Combining factorial and multi-arm multi-stage platform designs to evaluate multiple interventions efficiently.Clinical trials (London, England) · 2022Article
- Collaborative Platform Trials to Fight COVID-19: Methodological and Regulatory Considerations for a Better Societal Outcome.Clinical pharmacology and therapeutics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Global health pandemics, such as coronavirus disease 2019 (COVID-19), require efficient and well-conducted trials to determine effective interventions, such as treatments and vaccinations. Early work focused on rapid sequencing of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), subsequent
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.